Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Other Non-Current Liabilities: 2023-2024

Historic Other Non-Current Liabilities for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $1.7 million.

  • BioLineRx's Other Non-Current Liabilities fell 14.29% to $4.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.4 million, marking a year-over-year decrease of 14.29%. This contributed to the annual value of $1.7 million for FY2024, which is 85.83% down from last year.
  • As of FY2024, BioLineRx's Other Non-Current Liabilities stood at $1.7 million, which was down 85.83% from $11.9 million recorded in FY2023.
  • BioLineRx's Other Non-Current Liabilities' 5-year high stood at $11.9 million during FY2023, with a 5-year trough of $1.7 million in FY2024.
  • Over the past 2 years, BioLineRx's median Other Non-Current Liabilities value was $6.8 million (recorded in 2023), while the average stood at $6.8 million.
  • Data for BioLineRx's Other Non-Current Liabilities shows a maximum YoY slumped of 85.83% (in 2024) over the last 5 years.
  • BioLineRx's Other Non-Current Liabilities (Yearly) stood at $11.9 million in 2023, then crashed by 85.83% to $1.7 million in 2024.